Introduction: Cell repair dynamics are crucial in optimizing anti-cancer therapies. Various assays (eg, comet assay and γ-H2AX) assess post-radiation repair kinetics, but interpreting such data is challenging and model-based data analyses are required. However, ambiguities in parameter calibration remain an unsolved challenge. To address this, we propose combining survival dose-rate effects with computer simulations to gain knowledge about repair kinetics.
Methods: After a literature review, theoretical discriminators based on common fractionation/dose-rate-related effects were defined to discard unrealistic model dynamics. The Multi-Hit Repair (MHR) model was calibrated with canine osteosarcoma Abrams cell line data to study the discriminators' efficacy in scenarios with limited survival data. Additionally, survival dose-rate-dependent data from the human SiHa cervical cancer cell line were used to illustrate the survival behavior at diverse dose-rates and the capability of the MHR to model these data.
Results: SiHa data confirmed the validity of the proposed discriminators. The discriminators filtered 99% of parameter sets, improving the calibration of Abrams cells data. Furthermore, results from both cell lines may hint universal aspects of cellular repair.
Conclusions: Dose-rate theoretical discrimination criteria are an effective method to understand repair kinetics and improve radiobiological model calibration. Moreover, this methodology may be used to analyze diverse biological data using dynamic models .
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11367615 | PMC |
http://dx.doi.org/10.1177/15593258241279906 | DOI Listing |
Rep Pract Oncol Radiother
December 2024
Brachytherapy Department, Greater Poland Cancer Centre, Poznan, Poland.
Background: Treatment with sole ultra-low dose rate brachytherapy (uLDR-BT) for unfavorable intermediate risk factor (IUR) group prostate cancer patients is not recommended by guidelines due to the lack of strong evidence of its effectiveness. However, there were numerous patients treated with good results with this method in older trials. Purpose of this work was to retrospectively asses effectiveness of uLDR-BT in IUR group treated in our department.
View Article and Find Full Text PDFBrachytherapy
January 2025
Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Background: To determine outcomes of MRI-assisted radiosurgery (MARS) for salvage brachytherapy using the radioisotope Pd after various upfront treatments including surgery, external beam radiotherapy, and brachytherapy.
Methods: We retrospectively reviewed data for patients who underwent salvage MARS for intraprostatic lesions or prostate bed recurrences from 2016 to 2022. Biochemical recurrence, prostate cancer-specific, and overall survival, and the cumulative incidences of toxicities, were determined by Kaplan-Meier estimates.
Int J Radiat Biol
January 2025
N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Moscow, Russia.
Background: Enumeration of residual DNA repair foci 24 hours or more after exposure to ionizing radiation (IR) is often used to assess the efficiency of DNA double-strand break repair. However, the relationship between the number of residual foci in irradiated cells and the radiation dose is still poorly understood. The aim of this work was to investigate the dose responses for residual DNA repair foci in normal human fibroblasts after X-ray exposure in the absorbed dose range from 0.
View Article and Find Full Text PDFJ Cancer
January 2025
Department of Radiation Oncology, Nanyang Central Hospital, Nanyang, Henan, 473005, China.
Brachytherapy
December 2024
Department of Radiology, Wakayama Medical University, Wakayamashi, Wakayama, Japan.
Purpose: High-dose-rate brachytherapy (HDR-BT) combined with external beam radiotherapy (EBRT) is an effective treatment for patients with high- and very-high-risk prostate cancer. We sought to identify the factors associated with reduced biochemical recurrence rates following HDR-BT.
Methods: A total of 304 patients with high- or very-high-risk prostate cancer who underwent HDR-BT and EBRT were analyzed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!